Stem Cell Metabolites

Development of UC MSC-derived exosomes as a cell-free therapeutic agent

Since 2016, As the world had been established the mechanism of action of stem cells through paracrine signaling, SCI developed drug candidates from stem cell metabolites named secretome or conditioned medium which contains a lot of growth factors, chemokine, cytokine, and other proteins. In 2019, SCI went further research through the development of UC-MSC (umbilical cord mesenchymal stem cell)-derived exosomes as a cell-free therapeutic agent involves using exosomes, small membrane-bound vesicles, that are secreted by UC-MSCs to deliver therapeutic molecules to target cells. Exosomes contain a variety of bioactive molecules, such as proteins, lipids, and nucleic acids, which can regulate cellular processes and promote tissue repair. By isolating and purifying exosomes from UC MSCs, scientists can create a cell-free therapy that can be administered to patients without the need for cell transplantation that may have risk of rejection. UC MSC-derived exosomes have shown promise as a treatment for a variety of conditions, including neurological disorders, cardiovascular disease, and tissue injury. However, further research is needed to optimize the isolation and production of exosomes, as well as to understand their mechanisms of action and potential side effects.